Efficacy of Fertility‐Sparing Treatment With Progestin Is Associated With Different Molecular Classification in Endometrial Carcinoma and Atypical Endometrial Hyperplasia
Cancer Medicine · 2026
DOI: 10.1002/cam4.71875 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2026. Verfasst von Xue-Qian Qian und 4 weiteren Autor:innen. Beteiligte Einrichtung: Women's Hospital, Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Fertility Preservation, Endometrial Hyperplasia, Progestins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Key Research and Development Program of Zhejiang Province, Medical Science and Technology Project of Zhejiang Province, Basic Public Welfare Research Program of Zhejiang Province.
Abstract (Originalsprache)
Objective
To investigate the impact of various molecular characteristics on the outcomes of fertility‐preserving therapy in patients with endometrial cancer (EC) and atypical endometrial hyperplasia (AEH).
Methods
A total of 14 EC cases and 60 AEH cases were retrospectively analyzed at the Women's Hospital, Zhejiang University from January 2013 to October 2022.
Results
This study investigated the molecular profiles and outcomes of fertility preservation in 74 cases. The most prevalent molecular profile was NSMP type (63.9%), followed by p53abn type (21.3%) and MMRd type (14.8%). After 6 months of progesterone therapy, the cumulative CR rates were 100% for NSMP type, 83.3% for MMRd type, and 33.3% for p53abn type ( p = 0.006). The CR rate in the p53abn group was significantly lower than in the other two groups ( p = 0.006), with a notably higher recurrence rate ( p = 0.006). ER and PR expression was significantly lower in the MMRd and p53abn groups ( p = 0.002). A total of 26 pregnancies (42.6%) were observed. In the EC group, the pregnancy rate of p53abn was lower than that of the NSMP group (0% vs. 83.3%, p = 0.02). In the AEH group, pregnancy rates of p53abn and MMRd were not significantly different from the NSMP group (0% vs. 50%, p = 0.16; 33.3% vs. 50%, p = 0.20).
Conclusion
Molecular classification may serve as a predictive tool for the efficacy of fertility preservation therapy in patients with EC and AEH and was found to be particularly useful for identifying p53 mutants, which are associated with a high risk of recurrence, as well as MMRd types, which are known to lead to poor responses to progesterone treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Women's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
ORCID-Profile: Yuan-Ming Shen
Förderung
- Key Research and Development Program of Zhejiang Province
- Medical Science and Technology Project of Zhejiang Province
- Basic Public Welfare Research Program of Zhejiang Province
Zitieren
APA
Qian, X. Q., Fu, H. H., Wan, X. Y., Hu, D. X., & Shen, Y. M. (2026). Efficacy of Fertility‐Sparing Treatment With Progestin Is Associated With Different Molecular Classification in Endometrial Carcinoma and Atypical Endometrial Hyperplasia. Cancer Medicine. https://doi.org/10.1002/cam4.71875
Vancouver
Qian XQ, Fu HH, Wan XY, Hu DX, Shen YM. Efficacy of Fertility‐Sparing Treatment With Progestin Is Associated With Different Molecular Classification in Endometrial Carcinoma and Atypical Endometrial Hyperplasia. Cancer Medicine. 2026. doi:10.1002/cam4.71875
BibTeX
@article{Qian2026,
author = {Qian, Xue-Qian and Fu, Hao-Hui and Wan, Xiao-Yun and Hu, Dong-Xiao and Shen, Yuan-Ming},
title = {Efficacy of Fertility‐Sparing Treatment With Progestin Is Associated With Different Molecular Classification in Endometrial Carcinoma and Atypical Endometrial Hyperplasia},
journal = {Cancer Medicine},
year = {2026},
doi = {10.1002/cam4.71875}
}
EUVIMED